Looking at the filing, I need to extract financial data from the 10-Q. The filing content provided is primarily the cover page, table of contents, glossary, and cautionary statement. Let me assess the substantive disclosure content available. The filing does contain substantive content beyond boilerplate: share counts, exchange/ticker information, class structures, and references to specific financial items. However, the actual financial statements, MD&A figures, and segment data are listed in the table of contents but not included in the extracted text provided. I will work with what is present in the source text.

Molson Coors Beverage Company filed its Form 10-Q for the quarterly period ended June 30, 2026, with the U.S. Securities and Exchange Commission on August 6, 2026, disclosing share counts, capital structure details, and references to ongoing strategic and restructuring activities.

Key Highlights

  • Class B Common Stock outstanding: 174,117,990 shares as of July 30, 2026, according to the filing.
  • Class A Common Stock outstanding: 2,563,034 shares as of July 30, 2026, per the filing.
  • Canadian exchangeable shares: Molson Coors Canada Inc. had 2,678,963 Class A Exchangeable shares and 7,093,946 Class B Exchangeable shares outstanding as of July 30, 2026, traded on the Toronto Stock Exchange under symbols TPX.A and TPX.B, respectively.
  • Large accelerated filer: The registrant indicated it qualifies as a large accelerated filer under the Exchange Act definitions.
  • Americas Restructuring Plan: The filing references the Americas Restructuring Plan announced in October 2025, including expected charges and benefits, as a subject addressed in the MD&A section.
  • Registered securities: Class A Common Stock trades as TAP.A and Class B Common Stock trades as TAP on the New York Stock Exchange, with 3.800% Senior Notes due 2032 trading as TAP 32 on the New York Stock Exchange.

Molson Coors Capital Structure and Restructuring Activity in Q2 2026

Molson Coors Beverage Company (NYSE: TAP, NYSE: TAP.A), incorporated in Delaware and headquartered in Golden, Colorado, submitted its quarterly report for the period ended June 30, 2026. According to the filing, as of July 30, 2026, the company had 2,563,034 shares of Class A Common Stock and 174,117,990 shares of Class B Common Stock outstanding. Both classes carry a par value of $0.01 per share and are registered on the New York Stock Exchange.

The filing also discloses the structure of Molson Coors Canada Inc., a wholly-owned subsidiary. As of July 30, 2026, that subsidiary had 2,678,963 Class A Exchangeable shares and 7,093,946 Class B Exchangeable shares outstanding, traded on the Toronto Stock Exchange under TPX.A and TPX.B, respectively. The filing states these shares "are intended to provide substantially the same economic and voting rights as the corresponding class of Molson Coors common stock in which they may be exchanged." Voting rights for exchangeable shareholders are exercised through a Special Class A and Special Class B voting stock mechanism subject to a voting trust arrangement, as described in the filing.

Among the subjects addressed in the Management's Discussion and Analysis section, the filing lists the Americas Restructuring Plan, announced in October 2025, including "the expected charges and benefits of the restructuring." The filing also identifies macroeconomic forces, cost inflation and tariffs, commodity prices, consumer preferences, pricing trends, and environmental initiatives as topics covered in forward-looking statements within the MD&A. The company noted that such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995 and the company's own cautionary language.

What Was Disclosed

The quarterly filing covers the period ended June 30, 2026, and discloses share counts for all classes of common and exchangeable stock, the company's capital structure, exchange listings, and identifies the Americas Restructuring Plan and macroeconomic factors as subjects within the MD&A.